Navigation Links
Transgenomic Reports Second Quarter 2008 Results
Date:8/5/2008

Achieves Third Consecutive Quarter of Profitability

OMAHA, Neb., Aug. 5 /PRNewswire-FirstCall/ -- Transgenomic (OTC Bulletin Board: TBIO) today announced financial results for the quarter ended June 30, 2008. The Company reported net income of $101,000, or $0.00 per share, in the second quarter 2008, compared to net income of $226,000, or $0.00 per share, in the year ago period.

The second quarter of 2008 represented the Company's third consecutive quarter of profitability from continuing operations and reflects stable instrument and consumables revenues coupled with growth in the Company's Molecular Clinical Reference Laboratory and its Pharmacogenomics Services Laboratory businesses.

Craig Tuttle, Transgenomic's President and Chief Executive Officer, noted, "We are pleased to report the Company's third profitable quarter in a row, driven by significant growth in our laboratory services product line. We continue to build customer validation of our unique mutation discovery and detection service capabilities by increasing revenues from our reference lab and entering additional agreements for pharmacogenomic studies with large pharmaceutical partners. We are also looking for opportunities to enter into larger collaborations covering Phase III clinical trials that could generate significantly more revenue for the Company by enrolling much larger patient populations."

Second Quarter 2008

Net income from continuing operations was $101,000, or $0.00 per share, for the second quarter of 2008, compared to net income of $226,000, or $0.00 per share, for the second quarter of 2007. Net income for the year ago period consisted of $233,000, or $0.00 per share, from continuing operations and was offset by a loss of $7,000, or $0.00 per share, from discontinued operations related to the Company's sale of its Nucleic Acids operating segment and related assets. Net income in the second quarter of 2007 also included two non-recurrin
'/>"/>

SOURCE Transgenomic
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2007 Earnings Release Conference Call Webcast
3. Transgenomic, Inc. Forms Scientific Advisory Board
4. Transgenomic Appoints David Pauluzzi to Board of Directors
5. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
6. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
7. Transgenomic Opens Pharmacogenomics Laboratory in China
8. Webcast Alert: Transgenomic Inc. Announces First Quarter 2008 Earnings Release Conference Call Webcast
9. Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
10. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
11. Reminder: Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Based on the revenues gained ... market is dominated by four major players contributing ... These players include GE Healthcare (U.K.), Siemens AG ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... be attributed to its strong product portfolio, which ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Indianapolis, IN (PRWEB) December 17, 2014 ... for Laboratory Excellence following its most recent COLA ... Accreditation by COLA, a national healthcare accreditation organization. ... rigid standards of quality in day-to-day operations, demonstrate ... and pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 16, 2014  Vermillion, Inc. (NASDAQ: VRML ... today announced the next step in its expanded strategy ... provider with the naming of current Chief Operating Officer, ... Officer, while current Chairman of the Board and CEO ... Chairman. These changes are effective January 1, 2015. ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
... lecture and present a poster on proprietary siRNA ... targeting ... Quark Pharmaceuticals, Inc., a,development-stage pharmaceutical company discovering and developing ... the Cambridge Healthcare Institute,s 9th Annual Beyond,Genome Conference on ...
... than 30 years ago, when Northwestern University chemist Richard Van ... he would be using it to learn more about treasures ... watercolor recently featured in the museum,s exhibition "Watercolors by Winslow ... to be a Farmer,s Boy," painted in 1887, some of ...
... than $120,000 in the prestigious Race Across America the past two years, ... ... Wednesday, June 11,2008, Renato Shaffer will begin riding his bike for the third ... Disease, the fatal,brain disease that affects his wife and threatens his two daughters., ...
Cached Biology Technology:Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference 2Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference 3Northwestern chemist investigates lost reds in Homer painting 2HDSA-San Diego's Team 2CureHD Continues its Race to Cure Huntington's Disease 2
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... tissue and organ transplantation for diseases that are caused ... ethical discussions surrounding human embryonic stem cells, a lot ... (iPS cells). However, before this technique can be applied ... safety and efficacy of such iPS cells. VIB scientists ...
... omega-3 fatty acids can inhibit growth of breast cancer tumours ... University of Guelph. The study, published recently in the ... the first to provide unequivocal evidence that omega-3s reduce cancer ... professor in Guelph,s Department of Human Health and Nutritional Sciences, ...
... New analysis of data from the National Health ... the Centers for Disease Control and Prevention (CDC), indicates ... quality and nutrient intake level, lower intake of added ... "good cholesterol" levels and lower metabolic syndrome risk. These ...
Cached Biology News:Cell therapy a little more concrete thanks to VIB research 2Omega-3s inhibit breast cancer tumor growth, study finds 2New study indicates avocado consumption may be associated with better diet quality 2
... Protein Purification Protocols covers a wide ... for novice and experienced researchers in all ... This excerpt from the books preface illustrates ... to your research library., The chapters introduce ...
... Cellular uptake of long double stranded RNA ... interference in a diverse group of organisms ... RNA interference leads to the inhibition of ... of the target messenger RNA (mRNA). Attempts ...
... TrackerCumulates a score of movement counts, similar ... it.can track up to 6 subjects at once, ... triggered. Test a whole experimental group at ... the activity. Upgradeable for a variety of ...
... examining a novel object in the environment.The Spatial ... built around a video camera, frame grabber, and ... fields at once and up to 6 moving ... records them, but also allows video replay of ...
Biology Products: